Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and pharmacokinetic properties (the
absorption, distribution and excretion) of two preparations of aminopterin (0.25 mg tablets
and 1.0 mg tablets) following oral administration by subjects with moderate to severe
psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)